A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 914
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 11 Jul 2017 Planned End Date changed from 30 Jun 2023 to 7 Jul 2023.
- 11 Jul 2017 Planned primary completion date changed from 16 Jan 2023 to 5 Sep 2022.
- 11 Jul 2017 Status changed from not yet recruiting to recruiting.